N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 0.000p
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 832.28m
  • Volume: 0

Latest Deals

No deals were found in the last 365 days.

Largest Deals (365 days)

No deals were found in the last 365 days.

Director Shareholdings

Notifier Holding Value*
Nigel Theobald 12,389,919 £0
Luke Cairns 142,660 £0

Major Shareholders

Notifier** Holding Value*
TRACARTA LIMITED 150,000,000 £0
Northern Standard Limited 150,000,000 £0
Mathenz Marc Kay 74,000,000 £0
Patrick Byrne 43,162,500 £0
David Farrier 28,000,000 £0
Peel Hunt LLP 7,436,152 £0
MYLES MCNULTY 4,000,000 £0
Lynchwood Nominees Limited 690,800 £0
Barclays Stockbrokers Limited 447,800 £0
LR Nominees Limited 311,600 £0

* Value is calculated by using the current share price multiplied by the amount held.
** Major Shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.000p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 0.000p
52 Week Low 0.000p
Volume 0
Shares Issued 832.28m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.81% below the market average55.81% below the market average55.81% below the market average55.81% below the market average55.81% below the market average
70.73% below the sector average70.73% below the sector average70.73% below the sector average70.73% below the sector average70.73% below the sector average
Value
55.81% below the market average55.81% below the market average55.81% below the market average55.81% below the market average55.81% below the market average
70.73% below the sector average70.73% below the sector average70.73% below the sector average70.73% below the sector average70.73% below the sector average
Income Not Available
Growth
25.67% above the market average25.67% above the market average25.67% above the market average25.67% above the market average25.67% above the market average
17.24% above the sector average17.24% above the sector average17.24% above the sector average17.24% above the sector average17.24% above the sector average

N4 Pharma Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page